Pfizer has recently announced its decision to halt the development of danuglipron (PF-06882961), a candidate drug for obesity treatment.
Previously, Pfizer had discontinued a twice-daily oral obesity medication due to frequent nausea and vomiting side effects, which led to widespread patient discontinuation at the end of 2023. Since then, the company has been exploring various dosages of a once-daily version.
In a dose-optimization study involving 1,400 participants, Pfizer reported that danuglipron displayed liver enzyme elevations comparable to those seen with existing approved obesity drugs. However, one patient experienced liver damage.
This patient developed drug-induced liver injury but recovered after stopping danuglipron.
After thoroughly reviewing all clinical data related to danuglipron, Pfizer decided to terminate its development.
The company plans to present findings from the danuglipron clinical program at upcoming scientific conferences or academic journals. Pfizer will continue developing other oral obesity drug candidates that target the GIPR hormone.
Most Commented